Open AccessHepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study
Author(s) -
Lily Dubey,
Suparna Chatterjee,
Alakendu Ghosh
Publication year - 2016
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.190761
Subject(s) - medicine , adverse effect , leukopenia , rheumatoid arthritis , methotrexate , gastroenterology , alanine transaminase , concomitant , anemia , chemotherapy
Methotrexate (MTX) is the most commonly used cost-effective disease-modifying antirheumatoid drug (DMARD). Its main dose-limiting adverse effects are hepatic and hematopoietic. This cross-sectional, observational study evaluated the prevalence of hepatic and hematological adverse effects with long-term low-dose MTX therapy.